Atrium Therapeutics, Inc. (RNA)

NASDAQ

$7.76

$-0.46

(-5.54%)

After-Hours

Atrium Therapeutics, Inc. (RNA) Live Price Chart

Last updated: ⁦2026-10-13 20:25:40⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

Atrium Therapeutics, Inc. (RNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.76, with a market capitalisation of $143.69M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.63 to $73.06. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$143.69M
Open	$8.22
Day's High	$73.06
Day's Low	$3.43
Previous Close	$8.21
Volume	218.71K
Average Volume	257.09K
P/E Ratio	--
52-Week High	$73.06
52-Week Low	$7.63
Dividend Yield	--
Earnings Date	--

Atrium Therapeutics, Inc. (RNA) After-Hours Stock Price

Atrium Therapeutics, Inc. (RNA) is trading at $7.76 in after-hours trading as of 2026-10-13 19:56:22, down 5.48% ($0.45) from the regular-session close of $8.21.

After-hours trading shows how investors are pricing RNA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.

Atrium Therapeutics, Inc. (RNA) 7-Day Stock Price Change

Over the past seven days, Atrium Therapeutics, Inc. (RNA) moved from $7.84 to $7.76, representing a decline of 0.99% ($0.08).

The stock traded between $7.63 and $8.50 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.

The average daily volume was 321.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

RNA 52-Week Price Position

Position in Range: 0.2%

52W Low$7.63

52W High$73.06

RNA is currently trading at $7.76, placing it 0.2% of the way from its 52-week low of $7.63 to its 52-week high of $73.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Atrium Therapeutics, Inc. (RNA)?

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Atrium Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	391
Exchange	NASDAQ
Company Website	https://www.aviditybiosciences.com

How to Buy Atrium Therapeutics, Inc. (RNA) Stock on MEXC

Eligible investors can buy real shares of Atrium Therapeutics, Inc. (RNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for RNA and Place Your Order

Open the RealStocks trading page and search for RNA. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Atrium Therapeutics, Inc. (RNA) stock price today?

Atrium Therapeutics, Inc. (RNA) is currently trading at $ 7.76, down 5.46% ($0.45) from the previous close of $ 8.21. Intraday prices update in real time during regular trading hours.

2.Is RNA stock going up or down today?

As of 2026-10-13 19:56:22, RNA is trading at $ 7.76, down 5.46% ($0.45) from its previous close of $ 8.21. The stock has traded between $ 3.43 and $ 73.06 during today’s regular session. Past price movements do not guarantee future results.

3.What is RNA pre-market price?

As of 2026-10-13 19:56:22, RNA is trading at $ 8.25 in pre-market trading, up 0.50% ($0.04) from the previous close of $ 8.21. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is RNA after-hours price?

As of 2026-10-13 19:56:22, RNA is trading at $ 7.76 in after-hours trading, down 5.48% ($0.45) from the regular-session close of $ 8.21. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is RNA stock trading now?

RNA trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does RNA sit relative to its 52-week high and low?

Over the past 52 weeks, RNA has traded between a low of $ 7.63 and a high of $ 73.06. At $ 7.76, the stock is positioned 0.2% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Atrium Therapeutics, Inc. in?

Atrium Therapeutics, Inc. (RNA) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Atrium Therapeutics, Inc.'s market capitalisation and where is it listed?

Atrium Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 143.69M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is RNA valued in terms of P/E ratio and EPS?

RNA trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Atrium Therapeutics, Inc. pay a dividend?

Atrium Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.